Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Oxytocin Discontinuation
    ABSTRACT & COMMENTARY

    Oxytocin Discontinuation

    March 1, 2018
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Standard-Dose vs. High-Dose Oxytocin for Labor Augmentation

    Pharmacology Watch: Gender Differences with Anticoagulation Discontinuation

    Bone Loss Is Reversible in Women of All Ages After Discontinuation of Depot Medroxyprogesterone Acetate Injectable Contraception

    Related Products

    Preterm Premature Rupture of Membranes: When to Deliver?

    Embryo Implantation

    Glucose Screening: The Meaning of a Single Abnormal Value in a 3-hour Glucose Tolerance Test

    Keywords

    delivery

    cesarean

    oxytocin

    By John C. Hobbins, MD

    Professor, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora

    Dr. Hobbins reports no financial relationships relevant to this field of study.

    SYNOPSIS: A recent meta-analysis of randomized, clinical trials has shown that discontinuing oxytocin infusion once active labor has been attained in inductions and augmentations of labor will result in a reduction of cesarean delivery and tachysystole, but an increase in the length of labor.

    SOURCE: Saccone G, Ciardulli A, Baxter JK, et al. Discontinuing oxytocin infusion in the active phase of labor: A systematic review and meta-analysis. Obstet Gynecol 2017;130:1090-1096.

    The rate of induction of labor in the United States is about 23%.1 Since the uterus and cervix often are not ready for labor, it is not surprising that induction of labor is associated with an increased rate of cesarean delivery, which is now about 30%. Most often, the rationale for using oxytocin has been to initiate contractions and to assist in the transition into active phase. Oxytocin-driven tachysystole is not an uncommon (or innocuous) byproduct and can result in abnormal fetal heart rate patterns. This leaves one to wonder whether the labor medication is really needed once the uterus is on its own during the active stage of labor.

    Saccone et al undertook a meta-analysis of randomized, clinical trials (RCTs) comparing a protocol of a “business-as-usual” approach of continuing oxytocin through delivery against one in which the infusion was stopped once the active phase was attained. They analyzed data from nine RCTs involving 1,538 pregnancies, all of which had inductions of labor or augmentations with oxytocin. In one group, the infusion was discontinued once active labor was achieved, but if labor arrested (as defined by a plateauing of cervical dilatation over two hours) then it was restarted. In the other group (controls), the oxytocin was continued, generally at the same dosage, until delivery. Only three of the studies employed placebo control. In all studies, the definition of active labor was cervical dilatation of
    5 cm of greater.

    The meta-analysis included 764 patients in the discontinuation group and 774 patients in the control (continuation) group. An average of 30% in the discontinuation group had to have oxytocin restarted because of an arrest in dilatation, and the oxytocin infusion was stopped because of “fetal distress” in 7.7% of the control group. The authors were aware of the potential biases in this type of study, and they addressed the seven domains of bias described in the Cochrane Handbook for Systematic Reviews of Interventions.2

    The primary outcome measure was the cesarean delivery rate. The rate in the discontinuation group was 9.3% vs. 14.7% in the control group (relative risk [RR], 0.64; 95% confidence interval [CI], 0.48-0.87). Secondary outcomes included the rate of tachysystole, which was 6.2% vs. 13.1% (RR, 0.53; 95% CI, 0.33-0.38). The discontinuation group had an average active phase of labor that was 27.6 minutes longer than the control group (95% CI, 3.94-51.36 minutes). There were no significant differences in any of the other secondary variables evaluated.

    COMMENTARY

    In view of the high cesarean delivery rate, many common labor protocols have undergone re-evaluation. This has led to more liberal thresholds of tolerance for the lengths of active first and second stages of labor. Friedman’s original data suggested that the active phase started when patients had attained 4 cm of dilatation. In their recent labor guidelines,3 the American College of Obstetrics and Gynecology and the Society of Maternal Fetal Medicine increased the dividing line between the early and active phases of labor to 6 cm. Also, these guidelines indicate that providers should be more patient before considering intervention when progress in labor is sluggish. In fact, it was suggested that the label “arrest of labor” in the latent phase should not be used unless adequate contractions are attained for 12 to 18 hours following rupture of membranes and augmentation with oxytocin, if needed. Also, arrest of labor in the active phase now has been defined as no progress in dilatation after at least four hours of adequate contractions, thereby doubling the original threshold of two hours.

    The concept of stopping oxytocin once adequate contractions have been attained in strength and frequency not only appeals to patients who wish to experience a more natural labor, but it also may have some scientific merit. Two studies have suggested that after about 10 hours of induction, the oxytocin receptors may not respond, and further infusion even could have the opposite effect on contractions.4,5

    This meta-analysis has shown that the possible benefits from oxytocin discontinuation are lower rates of cesarean delivery and tachysystole. The downside is a longer length of labor, by an average of 27 minutes (or an addition of about eight to nine more contractions). Since the authors applied intention-to-treat methodology, the above data included the 30% in the discontinuation group whose infusion needed to be restarted.

    Is there a drawback to this practice? Prolonged labor has been associated, in general, with a higher rate of amnionitis and shoulder dystocia.6 Authors of one of the RCTs found a nonsignificant trend toward a higher rate of amnionitis. However, this and shoulder dystocia were not addressed in the other papers in the meta-analysis. That concern will need further study.

    The meta-analysis showed a 35% decrease in the cesarean delivery rate. When weighing the downside of an extra half hour of labor against a substantially lower chance of having a cesarean delivery, I would guess most patients would vote for stopping the oxytocin.

    REFERENCES

    1. Centers for Disease Control and Prevention. Recent declines in induction of labor by gestational age. Available at: https://www.cdc.gov/nchs/products/databriefs/db155.htm. Accessed Feb. 1, 2018.
    2. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available at: http://handbook.cochrane.org. Accessed Feb. 1, 2018.
    3. American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric care consensus no .1: Safe prevention of the primary cesarean delivery. Obstet Gynecol 2014;123:693-711.
    4. Phaneuf S, Rodriguez Linares B, Tamby-Raja RL, et al. Loss of myometrial oxytocin receptors during oxytocin-induced and oxytocin-augmented labour. J Reprod Fertil 2000;120:91-97.
    5. Robinson C, Schumann R, Zhang P, Young RC. Oxytocin-induced desensitization of the oxytocin receptor. Am J Obstet Gynecol 2003;188:497-502.
    6. Henry DE, Cheng YW, Shaffer BL, et al. Perinatal outcomes in the setting of active phase arrest of labor. Obstet Gynecol 2008;112:1109-1115.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    OB/GYN Clinical Alert

    View PDF
    OB/GYN Clinical Alert (Vol. 34, No. 11) – March 2018
    March 1, 2018

    Table Of Contents

    Fetal Fibronectin: Its Role in Threatened Preterm Labor

    Which Antibiotics Are Safe in the First Trimester of Pregnancy?

    Oxytocin Discontinuation

    Prevalence of Cognitive Impairment in Older Women With Pelvic Floor Disorders

    Begin Test

    Buy this Issue/Course

    Clinical Briefs in Primary Care

    Pharmacology Watch

    Financial Disclosure: OB/GYN Clinical Alert’s Editor, Jeffrey T. Jensen, MD, MPH, reports that he is a consultant for and receives grant/ research support from Bayer, Merck, ContraMed, and FHI360; he receives grant/research support from Abbvie, HRA Pharma, Medicines 360, and Conrad; and he is a consultant for the Population Council. Peer Reviewer Catherine Leclair, MD; Nurse Planners Marci Messerle Forbes, RN, FNP, and Andrea O’Donnell, FNP; Editorial Group Manager Terrey L. Hatcher; Executive Editor Leslie Coplin; and Editor Journey Roberts report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing